Author’s response to reviews

Title: A Randomized, Phase III Trial of Capecitabine plus Bevacizumab (Cape-Bev) versus Capecitabine plus Irinotecan plus Bevacizumab (CAPIRI-Bev) in First-Line Treatment of Metastatic Colorectal Cancer: The AIO KRK 0110 Trial / ML22011 Trial

Authors:

   Clemens Giessen (clemens.giessen@med.uni-muenchen.de)
   Ludwig Fischer von Weikersthal (weikersthal.ludwig@klinikum-amberg.de)
   Axel Hinke (axel.hinke@wisp.de)
   Sebastian Stintzing (sebastian.stintzing@med.uni-muenchen.de)
   Frank Kullmann (frank.kullmann@klinikum-nordoberpfalz.ag)
   Ursula Vehling-Kaiser (studien@vehling-kaiser.de)
   Julia Mayerle (mayerle@uni-greifswald.de)
   Markus Bangerter (markus.bangerter@hop-augsburg.de)
   Claudio Denzlinger (claudiodenzlinger@vinzenz.de)
   Markus Sieber (markus.sieber@kkh-gummersbach.de)
   Christian Teschendorf (christian.teschendorf@rub.de)
   Jens Freiberg-Richter (freiberg-richter@onkologie-dresden.net)
   Christoph Schulz (chris.schulz@med.uni-muenchen.de)
   Dominik P Modest (dominik.modest@med.uni-muenchen.de)
   Nicolas Moosmann (nicolas.moosmann@med.uni-muenchen.de)
   Philipp Aubele (philipp.aubele@med.uni-muenchen.de)
   Volker Heinemann (volker.heinemann@med.uni-muenchen.de)

Version: 3 Date: 20 August 2011

Author's response to reviews: see over
1. **Figure Titles**  
A figure title was placed after the references according to the major revisions in the formatting change guidelines.

2. **Microsoft Word track changes and highlighting**  
Microsoft Word track changes and highlighting has been removed from the manuscript.

3. **Abstract**  
Trial registration number has been placed in the abstract after the conclusion section. The subheading “Methods/Trial design” has been changed to “Methods/design”.

4. **Abbreviations**  
All given abbreviations were formatted in to a paragraph in alphabetical order.

5. **Acknowledgements**  
The subsections "Key staff at coordinating centre", “Protocol Committee” and "Participating Centres" were placed in the acknowledgements section and were formatted in to a paragraph.

6. **Authors contributions**  
The subsection “Authors contributions” has been formatted in to a paragraph.

7. **References**  
The reference list has been formatted and all authors and co-authors are mentioned if the number of authors is fewer than 30.